SCHEMBL624496

SCHEMBL624496

CC(C)COc1cc(N2CCN(C(=O)c3ccc4ccccc4n3)CC2)ncn1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.53
GAA P10253 2/20 0.52
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
MAPK1 P28482 1/20 0.50
RAB9A P51151 1/20 0.50
SCN7A Q01118 1/20 0.45
KCNH2 Q12809 1/20 0.45
GRIN2B Q13224 2/20 0.45
KDM4E B2RXH2 2/20 0.43
DPP4 P27487 1/20 0.43
DPP9 Q86TI2 1/20 0.43
SCN9A Q15858 2/20 0.43
CCKAR P32238 1/20 0.42
MAPT P10636 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MGLL Q99685 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL623189 0.89 PTK2 (0.51) TSHRGAADPP4SCN9AMEN1
SCHEMBL622785 0.86 GAA (0.41) TSHRGAAALDH1A1RAB9ASCN7A
SCHEMBL623221 0.86 SCN7A (0.49) TSHRGAAALDH1A1SMN1; SMN2SCN7A
SCHEMBL623165 0.85 CCKAR (0.44) TSHRALDH1A1DPP4CCKARMEN1
SCHEMBL623777 0.85 P2RY12 (0.46) TSHRMAPK1RAB9AKDM4EMGLL
SCHEMBL623245 0.85 TSHR (0.53) TSHRGAAALDH1A1SMN1; SMN2MAPK1
SCHEMBL623267 0.84 KCNK3 (0.43) TSHRALDH1A1SMN1; SMN2MAPK1KDM4E
SCHEMBL624539 0.84 MGLL (0.44) ALDH1A1SMN1; SMN2KCNH2KDM4EDPP4
SCHEMBL623746 0.83 KCNK3 (0.43) TSHRSMN1; SMN2MAPK1RAB9ACCKAR
SCHEMBL622299 0.83 ELOVL1 (0.40) TSHRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US claimed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US claimed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO claimed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-8999974-B2 Acyl piperazine derivatives as TTX-S blockers RAQUALIA PHARMA INC. (JP) 2015-04-07 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers RAQUALIA PHARMA INC. (JP) 2013-06-13 US disclosed
WO-2012020567-A1 ACYL PIPERAZINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130150356-A1 Acyl Piperazine Derivatives as TTX-S Blockers SCN5A, SCN2A, CACNA1G TSHR 1643/4885GAA 1067/4885ALDH1A1 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.